BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 17935664)

  • 1. Prognostic factors and staging systems of multiple myeloma:
    Tao ZF; Fu WJ; Yuan ZG; Wang DX; Chen YB; Hou J
    Chin Med J (Engl); 2007 Oct; 120(19):1655-8. PubMed ID: 17935664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Classification and prognostic evaluation in multiple myeloma. A retrospective study of relationship of survivals and responses to chemotherapy to immunological types, 20 single prognostic factors, 15 clinical staging systems, and 6 morphological classifications.
    Pasqualetti P; Colantonio D; Collacciani A; Casale R; Natali G
    Panminerva Med; 1991; 33(2):93-110. PubMed ID: 1923560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Long-term survival and prognostic factors in stage II-III multiple myeloma treated with conventional chemotherapy].
    Pertuiset E; Chevret S; Lioté F; Delauche MC; Bardin T; Dryll A; Kuntz D
    Ann Med Interne (Paris); 1992; 143(8):519-24. PubMed ID: 1303595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prognostic evaluation in multiple myeloma. Relationship between immunological types, single prognostic factors, clinical staging systems, morphological classification systems and survival].
    Pasqualetti P; Colantonio D; Casale R; Di Lauro G; Collacciani A; Festuccia V; Trotta A; Natali G
    Ann Ital Med Int; 1990; 5(3 Pt 1):195-204. PubMed ID: 2288822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prognostic factors in IgG and micromolecular multiple myeloma. Retrospective analysis of 50 consecutive cases].
    Pasqualetti P; Casale R; Colantonio D; Festuccia V; Di Lauro G; Natali G
    Minerva Med; 1987 May; 78(9):603-8. PubMed ID: 3587727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prognostic importance of beta-2-microglobulin in multiple myeloma].
    Avilés A; Zepeda G; Guzmán R; Talavera A; García EL; Díaz-Maqueo JC
    Rev Invest Clin; 1992; 44(2):215-20. PubMed ID: 1439309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stratification of multiple myeloma according to serum beta 2-microglobulin and serum albumin levels.
    Scudla V; Budíková M; Fischerová E; Zadrazil J; Indrák K
    Acta Univ Palacki Olomuc Fac Med; 1991; 130():201-12. PubMed ID: 1838869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prognostic effect of beta 2-microglobulin in multiple myeloma].
    Ortega F; González M; Moro MJ; Gascón A; Duarte I; Martín M; Hernández J; Jiménez-Galindo R; Portero JA; Sanz M
    Med Clin (Barc); 1992 Nov; 99(17):645-8. PubMed ID: 1447935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Serum beta 2-microglobulin in multiple myeloma. I. Relation to selected indicators, clinical stage and disease prognosis].
    Scudla V; Budíková M; Fischerová E; Raska I; Vavrdová V
    Vnitr Lek; 1991 Apr; 37(4):342-51. PubMed ID: 2053304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prognostic factors in multiple myeloma. Selection using multivariate analysis].
    Pasqualetti P; Colantonio D; Casale R; Lorenzetti G; Natali G
    Recenti Prog Med; 1989 Oct; 80(10):543-6. PubMed ID: 2602637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive value of interleukin-6 and neopterin in patients with multiple myeloma.
    Reibnegger G; Krainer M; Herold M; Ludwig H; Wachter H; Huber H
    Cancer Res; 1991 Dec; 51(23 Pt 1):6250-3. PubMed ID: 1933885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic factors affecting the survival of patients with multiple myeloma. A retrospective analysis of 86 patients.
    Rapoport BL; Falkson HC; Falkson G
    S Afr Med J; 1991 Jan; 79(2):65-7. PubMed ID: 1989088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Proposal of a new staging system using scoring of multiple myeloma].
    Pasqualetti P; Collacciani A; Casale R; Colantonio D
    Medicina (Firenze); 1989; 9(4):410-3. PubMed ID: 2634228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A comparison of staging classifications of plasmacytoma].
    Löffler H; Gassmann W; Haferlach T; Pralle H
    Onkologie; 1986 Aug; 9(4):196, 199-201. PubMed ID: 3531946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Evaluation of a morphologic staging method (myeloma progression score) in multiple myeloma].
    Pasqualetti P; Casale R; Collacciani A; Colantonio D
    Medicina (Firenze); 1989; 9(3):280-2. PubMed ID: 2615598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognosis of asymptomatic multiple myeloma.
    Alexanian R; Barlogie B; Dixon D
    Arch Intern Med; 1988 Sep; 148(9):1963-5. PubMed ID: 2458080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prognostic clinical and morphological classification of multiple myeloma (author's transl)].
    Wutke K; Rüdiger KD; Kelényi G
    Arch Geschwulstforsch; 1979; 49(8):671-84. PubMed ID: 543783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Prognostic factors in multiple myeloma].
    Pick AI; Tamir R; Vana D; Duczyminer-Kahana M; Weiss H; Lurie H; Dawidowich J; Meyerson E; Gelernter I
    Harefuah; 1990 Apr; 118(8):437-42. PubMed ID: 2358224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prognostic significance of skeletal lesions in multiple myeloma].
    Bettini R; Anzani P; Quadrelli CM; Mammano S; Rapazzini P; Marrapodi E; Sessa V
    Recenti Prog Med; 1989 Jun; 80(6):300-3. PubMed ID: 2672192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prognostic factors affecting survival in multiple myeloma].
    Tornóczky J; Tóth A; Sziládi E; Hoffmann E; Liszátz M
    Orv Hetil; 1990 Aug; 131(31):1679-84. PubMed ID: 2205822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.